Top Page
Central China New Life Ltd.
(9983)
Central China New Life Ltd. (9983) vs. iShares MSCI Hong Kong ETF (EWH)
Central China New Life Ltd. Business Overview & Revenue Model
Central China New Life Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.95B | 2.84B | 3.15B | 3.60B | 2.65B | Gross Profit |
| 652.77M | 757.09M | 1.04B | 1.18B | 860.72M | EBIT |
| 359.81M | -696.03M | 759.41M | 814.32M | 543.27M | EBITDA |
| 396.59M | -641.15M | 830.62M | 887.44M | 584.09M | Net Income Common Stockholders |
| 214.59M | -574.37M | 562.26M | 619.56M | 426.59M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.19B | 1.62B | 2.08B | 2.32B | 2.68B | Total Assets |
| 4.73B | 4.85B | 5.33B | 5.04B | 4.25B | Total Debt |
| 66.96M | 67.84M | 85.80M | 50.18M | 21.21M | Net Debt |
| -1.12B | -1.55B | -1.96B | -2.21B | -2.20B | Total Liabilities |
| 2.74B | 2.69B | 2.28B | 1.98B | 1.53B | Stockholders Equity |
| 1.86B | 2.05B | 2.94B | 2.95B | 2.69B |
| Cash Flow | Free Cash Flow | |||
| -4.53M | -89.89M | 290.92M | 145.45M | 257.20M | Operating Cash Flow |
| 3.86M | -77.09M | 308.66M | 178.44M | 281.27M | Investing Cash Flow |
| 893.00K | 18.46M | 126.84M | 245.64M | -532.82M | Financing Cash Flow |
| -429.37M | -370.14M | -675.63M | -360.51M | 2.00B |
Central China New Life Ltd. Technical Analysis
Central China New Life Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $17.34B | 10.59 | 3.20% | ― | ― | ||
71 Outperform | HK$13.08B | 17.64 | 8.94% | 3.60% | 1.01% | 12.45% | |
71 Outperform | €149.48B | 10.09 | 8.73% | 3.44% | -2.52% | 17.25% | |
68 Neutral | HK$3.27B | 6.32 | 9.70% | 7.97% | 2.68% | 8.49% | |
65 Neutral | HK$1.49B | 6.33 | 10.96% | 8.40% | 1.88% | ― | |
61 Neutral | $2.83B | 10.98 | 0.41% | 8438.90% | 5.81% | -21.06% | |
46 Neutral | €3.96B | ― | -29.17% | 2.54% | -11.94% | -756.32% |
Central China New Life Ltd. Corporate Events
Central China New Life Ltd. announced that all proposed resolutions at its Annual General Meeting on June 2, 2025, were approved by shareholders. Key resolutions included the approval of financial statements for the year ending December 31, 2024, the declaration of a final dividend, and the re-election of several directors. The approval of these resolutions supports the company’s operational stability and strategic direction, reinforcing its position in the market and providing assurance to stakeholders.
Central China New Life Ltd. has announced its annual general meeting scheduled for June 2, 2025, where shareholders will discuss and approve several key matters. These include the approval of the audited financial statements for 2024, the declaration of a final dividend, the re-election of directors, and the re-appointment of auditors. Additionally, the meeting will consider resolutions to authorize the directors to issue additional shares, which could impact the company’s capital structure and market positioning.
Central China New Life Ltd. announced significant changes in its executive leadership, with the resignation of Ms. Dai Jiling as Executive Director and CEO to focus on other responsibilities within the CCRE Group. Mr. Wang Jun has been appointed as the new CEO, bringing extensive experience in accounting, corporate finance, and investment banking. These leadership changes are expected to influence the company’s strategic direction and potentially impact its market positioning.
Central China New Life Limited has announced the composition of its board of directors, which includes five members with Mr. Wang Jun serving as the Chairman and CEO. The board also includes three independent non-executive directors, with various members serving on audit, remuneration, and nomination committees. This announcement highlights the company’s governance structure, which is crucial for its strategic direction and operational oversight.
Central China New Life Ltd. reported a revenue increase of 3.8% for the year ending December 31, 2024, reaching RMB2,952.2 million. Despite a decrease in gross profit by 15.4%, the company turned around its financial performance with a net profit of RMB238.2 million compared to a net loss in 2023. The company’s GFA under management grew by 8.3%, and it announced a final dividend of HK$7.36 cents per share, pending shareholder approval. This financial turnaround and expansion in managed GFA indicate a positive shift in the company’s operations and market positioning.
Central China New Life Ltd. has announced a final cash dividend of HKD 0.0736 per share for the financial year ending December 31, 2024. The dividend will be paid on June 25, 2025, following shareholder approval on June 2, 2025. This announcement reflects the company’s commitment to returning value to its shareholders, potentially impacting its market positioning positively by demonstrating financial stability and shareholder confidence.
Central China New Life Limited announced a positive profit alert, expecting a net profit between RMB215 million and RMB255 million for the year ended December 31, 2024, a significant improvement from a net loss of RMB578 million in 2023. This turnaround is primarily due to a substantial decrease in impairment losses on financial and contract assets. However, the core net profit attributable to shareholders is expected to decrease due to a decline in the business scale of value-added services to non-property owners.